Evaluation of Rapid ID Yeast Plus and API20C AUX systems in identification of yeast species,using molecular identification as ‘gold-standard’

Abstract

Abstract: Objective To conduct performance assessment on two commercialised kits for yeast identification: Rapid ID Yeast Plus (RapID YS) and API20C AUX (API20C), using molecular Methods as "gold standard".Methods A total of 194 strains of 2 yeast species were selected from China Hospital Invasive Fungal Surveillance Net (CHIF-NE) 2010 strain collection, which includes 130 strains of the five commonest species (Candida albicans,Candida tropicalis,Candida glabrata,Candida parapsilosis,Cryptococcus neoformans) that constitute 67% of the total. All strains were identified to species level by molecular methods. Identification by RapID YS and API20C were parallel conducted according to the product manufacturer's instructions.Results Amongst the isolates studied, 181 (18 species) were within the RapID YS identification database, and 87.8% (19/181 isolates) was correctly identified to species or species complex level. Comparatively, API20C database compassing a total of 174 strains (18 species), and 92.0% (160/174 isolates) was correctly identified to species or species complex level. For the five commonest yeast species, the correct identification rate of RapID YS and API20C, to species level, was 93.1% and 97.1%, respectively. For spe-cies not included in identification database, the incorrect identification rate was 23.1% (3/13) for RapID YS, and 60.0% (12/20) for API20C AUX. Overall, no significant difference was observed between two commercial Methods (McNemar test,P>0.0).Conclusions he identification capability of two commercial Methods were basically the same. RapID YS held relatively greater advantages in terms of operational convenience and turn-around time for. It possesses comprehensive application prospects for clinical applications.

Key words: invasive fungal infection, yeast, Rapid ID Yeast Plus, API20C AUX, molecular identification

CLC Number:

R446.53

FAN Xin, WANG He, SU Xiao-xiang, XIAO Meng, MA Xue-fei, MA Chao-yue, LIU Xu-guang, MA Ran, WU Yue, CHEN Yan-zhao, XU Ying-chun. Evaluation of Rapid ID Yeast Plus and API20C AUX systems in identification of yeast species,using molecular identification as ‘gold-standard’[J]. Chinese Journal of Mycology, 2013, 8(5): 274-280.

References

[1] Miceli MH,Diaz JA,Lee SA,Emerging opportunistic yeast infections[J]. Lancet Infect Dis,2011,11(2):142-151.
[2] Wisplinghoff H,Bischoff T,Tallent SM,et al.Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004,39(3)309-317.
[3] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol,2012,50(12):3952-3959.
[4] bioMérieux api®20C AUX Yeast Identification System instructions (07628H-en-2010/02).
[5] Remel RapIDTM Yeast Plus System instructions (REF R8311007).
[6] Ahmad S,Khan Z.Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods[J]. Indian J Med Microbiol,2012,30(3):264-269.
[7] Brizendine KD,Baddley JW,Pappas PG.Pulmonary cryptococcosis[J]. Semin Respir Crit Care Med,2011,32(6):727-734.
[8] Hidron AI,Edwards JR,Patel J,et al.NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007[J]. Infect Control Hosp Epidemiol,2008,29(11):996-1011.
[9] Sievert DM,Ricks P,Edwards JR,et al.Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010[J]. Infect Control Hosp Epidemiol,2013,34(1):1-14.
[10] Baskova L,Buchta V.Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach[J]. Folia Microbiol (Praha),2012,57(5):421-430.
[11] Garey KW,Rege M,Pai MP,et al.Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study[J]. Clin Infect Dis,2006,43(1):25-31.
[12] Guo LN,Xiao M,Kong F,et al.Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China[J]. J Clin Microbiol,2011,49(11):3805-3811.
[13] Espinel-Ingroff A,Stockman L,Roberts G,et al.Comparison of RapID yeast plus system with API 20C system for identification of common, new, and emerging yeast pathogens[J]. J Clin Microbiol,1998,36(4):883-886.
[14] Heelan JS,Sotomayor E,Coon K,et al.Comparison of the rapid yeast plus panel with the API20C yeast system for identification of clinically significant isolates of Candida species[J]. J Clin Microbiol,1998,36(5):1443-1445.
[15] Kitch TT,Jacobs MR,McGinnis MR,et al.Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours[J]. J Clin Microbiol,1996,34(5):1069-1071.
[16] Sanguinetti M,Porta R,Sali M,et al.Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory[J]. J Clin Microbiol,2007,45(4):1343-1346.
[17] Smith MB,Dunklee D,Vu H,et al.Comparative performance of the RapID Yeast Plus System and the API 20C AUX Clinical Yeast System[J]. J Clin Microbiol,1999,37(8):2697-2698.
[18] Wadlin JK,Hanko G,Stewart R,et al.Comparison of three commercial systems for identification of yeasts commonly isolated in the clinical microbiology laboratory[J]. J Clin Microbiol,1999,37(6):1967-1970.
[19] Pfaller MA,Diekema DJ,Gibbs DL,et al.Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005[J]. J Clin Microbiol,2008,46(2):515-521.
[20] Castanheira M,Woosley LN,Diekema DJ,et al.Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs[J]. J Clin Microbiol,2013,51(1):117-124.
[21] Lohmann C,Sabou M,Moussaoui W,et al.Comparison between the Biflex III-Biotyper and the Axima-SARAMIS systems for yeast identification by MALDI-TOF mass spectrometry[J]. J Clin Microbiol,2013, 51(4):1231-1236.
[22] Buchan BW,Ledeboer NA.Advances in the Identification of Clinical Yeast Isolates Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry[J]. J Clin Microbiol,2013, 51(5):1359-1366.
[23] Steensels D,Verhaegen J,Lagrou K.Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological laboratory: a review[J]. Acta Clin Belg,2011,66(4):267-273.